Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Ways to track down the Right Criminal Legal counselor - 2Emergency services search for five people last seen in missing Jeep
- 3Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- 4Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- 5Careful Living: Embracing the Current Second
- Australian State Triggers Emergency Powers Amid Fuel Crisis
- Find the Advantages of Deep rooted Getting the hang of: Extending Information and Self-awareness
- Hanwha Ocean secures orders worth $866m for five vessels
- New ‘Cloud-9’ object could reveal the secrets of dark matter
- South Africa pushes for $200B investment
- First Phosphate advances battery-grade phosphate project as analysts highlight strategic Federal support
- What's Your Number one Superhuman Film Made?
- EU Council president: Ukraine should receive binding guarantees
- Figure out How to Really focus on Your Dental Inserts for Durable Outcomes
